Lab study reveals how HIV drug crosses the placenta

NCT ID NCT02020083

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study used donated placentas from 369 pregnant women to understand how the HIV drug tenofovir moves from mother to baby. Researchers used a special lab model that mimics the third trimester of pregnancy. The goal was to see if certain proteins or drug interactions affect how much tenofovir reaches the fetus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tenofovir

What this could lead to

If successful, this could help doctors understand how tenofovir moves through the placenta, potentially leading to safer use of this drug during pregnancy.

What could go wrong

This is a lab study using donated placentas, not a treatment trial. Results may not fully reflect what happens in the body, and the study does not test any new drug or therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Maternité de Port Royal

    Paris, France